Friday, July 31, 2026

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

Samsung SDI to Sign $894M Contract With NextEra Energy

Samsung SDI will be signing a battery...

Major Investment Banks Forecast U.S. Interest Rates Drop After September

U.S. interest rate cuts are delayed post-September due to inflation concerns from rising oil prices, affecting forecasts from major banks.

Tag: obesity treatment

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Novo Nordisk’s Oral Wegovy Tops 3,000 Prescriptions in Its First Week—A Challenge to Injectable GLP-1s

Novo Nordisk's Wegovy oral treatment exceeds 3,000 prescriptions in its debut week, signaling a shift towards oral obesity medications.

Weight-Loss Drugs Could Cut Airline Fuel Bills by $580 Million—An Unexpected Win for U.S. Carriers

The obesity treatment market is growing, helping U.S. airlines save on fuel costs due to decreased passenger weight.

Patches, Implants, and Oral Films… The Drug-Delivery Format Battle After Oral Wegovy

Oral Wegovy's launch is transforming obesity treatment, focusing on user-friendly delivery methods and enhancing patient adherence.

Is RPG-102 the Future of Obesity Treatment? Discover the Breakthrough Oral Solution!

ProGen and Rani Therapeutics initiate a Phase 1 trial for RPG-102, an oral obesity treatment, aiming for effective weight loss with weekly dosing.

New Obesity Pill Could End Wegovy’s Reign, Offering Faster and Safer Results

Ildong's ID110521156 shows promise as an affordable GLP-1 obesity drug with fewer side effects, aiming to transform the treatment landscape.

Wegovy Gets Stronger: New Dose Promises Even More Weight Loss

Novo Nordisk's new high-dose Wegovy aims to enhance obesity treatment, with promising trial results and a strategic EU rollout planned.

As Wegovy and Mounjaro Soar, Korean Biotechs Seek a Slice of the Obesity Drug Market

South Korean firms are innovating in the GLP-1 obesity treatment market, developing unique drugs to compete with industry leaders.

New Obesity Drug Shows Big Promise — and It’s Not from Eli Lilly or Novo

Metsera leads emerging obesity treatments with promising drug MET-233i, showing significant weight loss in trials, amid rising competition.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

ProGen’s PG-110 Targets Fat Loss Without Muscle Waste—Next-Gen Obesity Drug in Focus

ProGen will present non-clinical results of its obesity drug PG-110 at the ADA conference, targeting muscle preservation and weight loss.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.